Dr Reddys Non Current Assets Total Over Time
| RDY Stock | USD 14.20 0.21 1.50% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Dr Reddys Performance and Dr Reddys Correlation. RDY |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dr Reddys. If investors know RDY will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dr Reddys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.15) | Dividend Share 8 | Earnings Share 0.78 | Revenue Per Share 60.1437 | Quarterly Revenue Growth 0.165 |
The market value of Dr Reddys Laboratories is measured differently than its book value, which is the value of RDY that is recorded on the company's balance sheet. Investors also form their own opinion of Dr Reddys' value that differs from its market value or its book value, called intrinsic value, which is Dr Reddys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dr Reddys' market value can be influenced by many factors that don't directly affect Dr Reddys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dr Reddys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dr Reddys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dr Reddys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Non Current Assets Total Analysis
Compare Dr Reddys Laboratories and related stocks such as Pacira BioSciences,, Phibro Animal Health, and Collegium Pharmaceutical Non Current Assets Total Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PCRX | 31.2 M | 30.8 M | 51.1 M | 63.1 M | 111.8 M | 137 M | 148.4 M | 237.3 M | 211.4 M | 422.5 M | 622.9 M | 1.2 B | 1.2 B | 1.1 B | 1.1 B |
| PAHC | 108.7 M | 139 M | 177.8 M | 173 M | 179.6 M | 267.5 M | 259.7 M | 256.2 M | 260.5 M | 332.3 M | 342.4 M | 365.5 M | 385.7 M | 381.2 M | 224.4 M |
| COLL | 773 K | 773 K | 773 K | 773 K | 594 K | 835 K | 3.4 M | 2.1 M | 53.7 M | 50.6 M | 366 M | 376.5 M | 754.1 M | 605.7 M | 636 M |
| ANIP | 532.8 K | 4.4 M | 3.6 M | 16.8 M | 60.2 M | 92.7 M | 219.9 M | 280.5 M | 277.7 M | 269.1 M | 290.9 M | 449.8 M | 415.8 M | 384.6 M | 403.8 M |
| ALKS | 9.3 M | 1.1 B | 1.1 B | 1 B | 874 M | 836.7 M | 813.8 M | 831.2 M | 761 M | 764 M | 814 M | 732.9 M | 702.1 M | 650.7 M | 423.1 M |
| ITCI | 189 K | 189 K | 189 K | 199.8 K | 125.5 K | 847.4 K | 703.4 K | 2.3 M | 1.8 M | 20.9 M | 26.4 M | 22.6 M | 16.8 M | 60.5 M | 63.5 M |
| PBH | 295.9 M | 1.6 B | 1.6 B | 1.6 B | 2.5 B | 2.7 B | 3.6 B | 3.5 B | 3.1 B | 3.1 B | 3.2 B | 3.4 B | 3 B | 2.9 B | 2.2 B |
| EVO | 7 M | 134.9 M | 137.3 M | 104.9 M | 99.3 M | 121.6 M | 182.1 M | 487 M | 522.1 M | 711.4 M | 804.1 M | 1.1 B | 1.2 B | 1.4 B | 1.5 B |
| SUPN | 7.7 M | 4.3 M | 2.2 M | 13.8 M | 28.6 M | 82.8 M | 158.2 M | 196 M | 484.3 M | 687.6 M | 873.7 M | 1.1 B | 968.4 M | 784.6 M | 823.8 M |
Dr Reddys Laboratories and related stocks such as Pacira BioSciences,, Phibro Animal Health, and Collegium Pharmaceutical Non Current Assets Total description
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.My Equities
My Current Equities and Potential Positions
| Dr Reddys Laboratories | RDY |
| Classification | Obamacare |
| Location | India |
| Exchange | New York Stock Exchange |
USD 14.2
Additional Tools for RDY Stock Analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.